Tyra Biosciences: FDA ODD Designation Progresses TYRA-300
Seeking Alpha,
Summary Tyra's net loss continues to improve in Q2 2023. TYRA-300 has been granted Orphan Drug Designation status by the FDA…
Summary Tyra's net loss continues to improve in Q2 2023. TYRA-300 has been granted Orphan Drug Designation status by the FDA…
Summary ArQule is a small cap biotech that develops small molecule kinase inhibitors.